Cargando…

Lacrimal sac adenocarcinoma managed with androgen deprivation

PURPOSE: To describe a case of primary lacrimal sac adenocarcinoma treated primarily with androgen deprivation therapy (ADT) with good clinic response. OBSERVATIONS: An 82-year-old male presented with a painless right orbital mass. Pathology following partial resection was consistent with primary la...

Descripción completa

Detalles Bibliográficos
Autores principales: Abramson, David H., Fallon, Julia, Biran, Noa, Francis, Jasmine H., Jaben, Korey, Oh, William K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393461/
https://www.ncbi.nlm.nih.gov/pubmed/32760849
http://dx.doi.org/10.1016/j.ajoc.2020.100607
_version_ 1783565050607304704
author Abramson, David H.
Fallon, Julia
Biran, Noa
Francis, Jasmine H.
Jaben, Korey
Oh, William K.
author_facet Abramson, David H.
Fallon, Julia
Biran, Noa
Francis, Jasmine H.
Jaben, Korey
Oh, William K.
author_sort Abramson, David H.
collection PubMed
description PURPOSE: To describe a case of primary lacrimal sac adenocarcinoma treated primarily with androgen deprivation therapy (ADT) with good clinic response. OBSERVATIONS: An 82-year-old male presented with a painless right orbital mass. Pathology following partial resection was consistent with primary lacrimal sac adenocarcinoma positive for androgen receptors (AR). Magnetic resonance imaging (MRI) scan showed an orbital mass with extension into the nasolacrimal apparatus and intraconally between the medial and inferior recti. Staging positron emission tomography/computed tomography (PET/CT) showed one hypermetabolic right sided lymph node in addition to the known orbital mass. Orbital exenteration and external beam radiation therapy were offered as the primary treatment modality however the patient refused. He subsequently received four years of androgen deprivation monotherapy, before stopping due to sexual side effects, with no progression of local or metastatic disease and some local regression documented on MRI at 5 years. CONCLUSIONS AND IMPORTANCE: Lacrimal sac adenocarcinoma is commonly found to be AR positive on pathology. Our case shows that ADT can serve as an effective treatment modality for those patients that defer primary surgical management.
format Online
Article
Text
id pubmed-7393461
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-73934612020-08-04 Lacrimal sac adenocarcinoma managed with androgen deprivation Abramson, David H. Fallon, Julia Biran, Noa Francis, Jasmine H. Jaben, Korey Oh, William K. Am J Ophthalmol Case Rep Case Report PURPOSE: To describe a case of primary lacrimal sac adenocarcinoma treated primarily with androgen deprivation therapy (ADT) with good clinic response. OBSERVATIONS: An 82-year-old male presented with a painless right orbital mass. Pathology following partial resection was consistent with primary lacrimal sac adenocarcinoma positive for androgen receptors (AR). Magnetic resonance imaging (MRI) scan showed an orbital mass with extension into the nasolacrimal apparatus and intraconally between the medial and inferior recti. Staging positron emission tomography/computed tomography (PET/CT) showed one hypermetabolic right sided lymph node in addition to the known orbital mass. Orbital exenteration and external beam radiation therapy were offered as the primary treatment modality however the patient refused. He subsequently received four years of androgen deprivation monotherapy, before stopping due to sexual side effects, with no progression of local or metastatic disease and some local regression documented on MRI at 5 years. CONCLUSIONS AND IMPORTANCE: Lacrimal sac adenocarcinoma is commonly found to be AR positive on pathology. Our case shows that ADT can serve as an effective treatment modality for those patients that defer primary surgical management. Elsevier 2020-07-24 /pmc/articles/PMC7393461/ /pubmed/32760849 http://dx.doi.org/10.1016/j.ajoc.2020.100607 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Abramson, David H.
Fallon, Julia
Biran, Noa
Francis, Jasmine H.
Jaben, Korey
Oh, William K.
Lacrimal sac adenocarcinoma managed with androgen deprivation
title Lacrimal sac adenocarcinoma managed with androgen deprivation
title_full Lacrimal sac adenocarcinoma managed with androgen deprivation
title_fullStr Lacrimal sac adenocarcinoma managed with androgen deprivation
title_full_unstemmed Lacrimal sac adenocarcinoma managed with androgen deprivation
title_short Lacrimal sac adenocarcinoma managed with androgen deprivation
title_sort lacrimal sac adenocarcinoma managed with androgen deprivation
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393461/
https://www.ncbi.nlm.nih.gov/pubmed/32760849
http://dx.doi.org/10.1016/j.ajoc.2020.100607
work_keys_str_mv AT abramsondavidh lacrimalsacadenocarcinomamanagedwithandrogendeprivation
AT fallonjulia lacrimalsacadenocarcinomamanagedwithandrogendeprivation
AT birannoa lacrimalsacadenocarcinomamanagedwithandrogendeprivation
AT francisjasmineh lacrimalsacadenocarcinomamanagedwithandrogendeprivation
AT jabenkorey lacrimalsacadenocarcinomamanagedwithandrogendeprivation
AT ohwilliamk lacrimalsacadenocarcinomamanagedwithandrogendeprivation